Efficacy, Safety and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Phase 3
942
about 4.4 years
40–80
48 sites in AZ, CA, FL +14
What this study is about
This trial is testing a treatment called lunsekimig compared to a placebo in adults with COPD that can't be controlled. The goal is to see if lunsekimig helps improve symptoms and is safe for people with COPD.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Lunsekimig
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: Change from baseline in post-Bronchodilator Forced Expiratory Volume in 1 second (post-BD FEV1), Change from baseline in pre-Bronchodilator Forced Expiratory Volume in 1 second (pre-BD FEV1), Change from baseline in the Chronic airways assessment Test (CAAT) score, Change from baseline in the E-RS:COPD total score, Change from baseline in the SGRQ-C total score, Incidence of participants with TEAEs, including AESIs, and SAEs
Respiratory